Autosomal Recessive Congenital Ichthyosis (ARCI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Autosomal Recessive Congenital Ichthyosis (ARCI) Market Outlook

Thelansis’s “Autosomal Recessive Congenital Ichthyosis (ARCI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Autosomal Recessive Congenital Ichthyosis (ARCI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Autosomal Recessive Congenital Ichthyosis (ARCI) Overview

Autosomal recessive congenital ichthyosis (ARCI) is a heterogeneous group of keratinization disorders recognized by abnormal skin scaling over the entire body and classified as non-syndromic and syndromic forms of ichthyosis. ABCA12, ALOX12B, ALOXE3, CASP14, CERS3, CYP4F22, LIPN, NIPAL4, PNPLA1, SDR9C7, SLC27A4, and TGM1 are the twelve genes known to be involved with ARCI; at least 15% of affected families do not have pathogenic variants in any of the known genes. 60% to 70% of the patients have severe symptoms such as collodion membrane at birth. The two main phenotypes are lamellar ichthyosis and congenital ichthyosiform erythroderma; however, phenotypic overlap can occur in the same patient or patients from the same family. Some patient exhibits nonlamellar, non-erythrodermic ichthyosis. It also includes harlequin ichthyosis, acral self-healing collodion baby, self-healing collodion baby, and bathing suit ichthyosis.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Autosomal Recessive Congenital Ichthyosis (ARCI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034